Exicure (XCUR) Total Current Liabilities (2016 - 2026)
Exicure's (XCUR) quarterly Total Current Liabilities came in at $4.5 million in Q1 2026, up 14.68% YoY from $3.9 million in Q1 2025, and up 14.71% on a QoQ basis from $3.9 million in Q4 2025.
Exicure (XCUR) Total Current Liabilities (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Total Current Liabilities data on file, last reported at $4.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 14.68% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 14.68% YoY) and the FY2025 annual result came in at $3.9 million, up 26.6% from the prior year.
- Total Current Liabilities climbed to $4.5 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $25.7 million in Q3 2022 to a low of $1.4 million in Q2 2023.
- A 5-year average of $6.4 million and a median of $3.4 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 95.19% — and 2024, when it surged 139.76%.
- Tracing XCUR's Total Current Liabilities over 5 years: stood at $1.6 million in 2022, then surged by 53.14% to $2.5 million in 2023, then grew by 22.35% to $3.1 million in 2024, then gained by 26.6% to $3.9 million in 2025, then increased by 14.71% to $4.5 million in 2026.
- The last three Total Current Liabilities figures came in at $4.5 million (Q1 2026), $3.9 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Exicure | 8.41 Mn | 8.41 Mn | - | 4.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.46 Mn |
| Dec 31, 2025 | 3.89 Mn |
| Sep 30, 2025 | 2.77 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 1.43 Mn |
| Mar 31, 2023 | 2.73 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 25.71 Mn |
| Jun 30, 2022 | 19.66 Mn |
| Mar 31, 2022 | 21.36 Mn |
| Dec 31, 2021 | 34.07 Mn |
| Sep 30, 2021 | 21.98 Mn |
| Jun 30, 2021 | 12.75 Mn |